HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups.

Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.

While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.

Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.

In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.

The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.

Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estim
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:8/28/2014)... 2014 In the healthcare industry, there ... struggle with: How can the overall quality of patient ... of the healthcare industry tackles this question, and has ... job satisfaction and the quality of patient care. ... in “ Organizational Factors related to Improving Quality of ...
(Date:8/28/2014)... August 28, 2014 Tea Leaves ... with Gigya, the leader in Connected Consumer Management. ... Leaves will have the opportunity to build more ... who they are and how they like to ... the world’s biggest brands to understand and connect ...
(Date:8/28/2014)... Livermore, CA (PRWEB) August 28, 2014 ... newest California physician, James Patel M.D. of Livermore, California. ... the best and most qualified physicians, and in accordance ... and our patients to Dr. Patel’s practice. , Initially ... at a young age, Dr. Patel was shaped by ...
(Date:8/28/2014)... 2014 The need for larger space has ... few years. The new location - 4700 Bryant Irvin Court, ... larger office space than TLC had in the past, as ... pleased about our new location because it represents a good ... be double in size compared to the current one, the ...
(Date:8/27/2014)... August 28, 2014 Author and orthopedic ... takes readers on the thrilling adventures of sharp and ... in 2012, is gearing up for a new marketing ... into two novellas , “Prescription: Murder” follows the ... finds himself dodging assassination attempts and thwarting criminals. In ...
Breaking Medicine News(10 mins):Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4Health News:Tea Leaves Health Begins Important New Partnership with Gigya 2Health News:Tea Leaves Health Begins Important New Partnership with Gigya 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:William H. Simon Launches New Marketing Campaign for Book 2
(Date:8/27/2014)... , Aug. 27, 2014 TWi ... final approval from the United States Food and ... Application (ANDA) for megestrol acetate 125mg/ml oral suspension, ... TWi is the first-to-file and under Hatch Waxman ... of marketing exclusivity.  TWi has completed the pre-launch ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a ... Terms & Agreements in Pharma, Biotech and ... The Co-development Terms and Agreements in ... understanding and unprecedented access to the co-development ... worlds leading life science companies. The ...
(Date:8/27/2014)... and MENLO PARK, Calif. , ... (OTCQB: DMPI), developer of advanced cancer therapeutics , ... 16th Annual Rodman & Renshaw Global Investment Conference, sponsored ... will take place Tuesday, September 9th at 2:55 p.m. ... the New York Palace Hotel in New ...
Breaking Medicine Technology:TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4
Cached News: